Why GLP-1s can be a 'half a trillion dollar market': Tema ETF CEO

Weight-loss drugs known as GLP-1s have been estimated by some to be a $100 billion market by 2030, but could it actually be worth 5x that amount? Tema ETFs Founder and CEO Maurits Pot joins Market Domination to give insight into the GLP-1 market, what makes it so valuable, what are some of its applications, and why investors need to pay attention to the companies making them.  He says there are a couple of ways the market can become a half-trillion-dollar one. First, the expected increase in the number of obese people around the globe. Second is how the drugs could be used to treat and address other disorders. He continues: "So simplistically, if we just think about, let's say that's just a billion people, let's say that 20% of people by 2030 are on the drug. Today that's 2%. So that's 10X the penetration from today. And let's say that pricing drops by 60% below $5,000 a year, based on those numbers alone, we get to about a half a trillion plus market. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Nicholas Jacobino